Article Annexe 11-2 (suite 3)
…g: functional class II+ or III), clear alteration of echographicechographic or echodoppler parameters. Exercise intolerance with stress ECG abnormalities35 à 40 %Idem, with significant therapeutic con…
20+ full codes, 2,400+ articles translated and updated. Case law linked to every article. Read the actual text before you ask a lawyer about it — free, no login required.
20+
french codes
Fully translated
2,400+
articles in English
Updated regularly
480+
court rulings linked
Per article
Free
full access
No login required
Showing 221–230 of 1584 articles for “Art. s. 150 VF”
…g: functional class II+ or III), clear alteration of echographicechographic or echodoppler parameters. Exercise intolerance with stress ECG abnormalities35 à 40 %Idem, with significant therapeutic con…
…D. 1142-2 VI. - LOCOMOTOR SYSTEMFIRST PART: PREHENSIONThe gripping function is performed by the hands. The mobility of the other segments of the upper limbs essentially has the effect of projecting th…
…replacement by a mobile prosthesis and by two-thirds in the case of replacement by a fixed prosthesis.In the event of complete loss of a tooth replaced by an implant-supported prosthesis: 0%.Pulpal mo…
…ny company or organisation exploiting a medicinal product or a product mentioned in Article R. 5121-150 : 1° Implements a risk management system for each medicinal product or each product for which th…
For the medicinal products mentioned in 1° of II of article L. 5121-12 and in II of article L. 5121-12-1, the obligations set out in article R. 5121-161 and articles R. 5121-166 to R. 5121-170 are car…
…ny company or organisation exploiting a medicinal product or a product mentioned in Article R. 5121-150 shall implement a pharmacovigilance system in order to fulfil its pharmacovigilance obligations,…
…ny company or organisation exploiting a medicinal product or a product mentioned in Article R. 5121-150 is required to: 1° Record all adverse reactions suspected of being due to a medicinal product or…
…company or organisation exploiting a medicinal product or a product referred to in Article R. 5121-150 has at its disposal on a permanent basis the services of a person responsible for pharmacovigila…
…tion useful for assessing the risks and benefits associated with the use of the products that he uses.
…company or organisation exploiting a medicinal product or a product referred to in Article R. 5121-150 may not communicate information relating to pharmacovigilance to the general public about this m…
Avocate au Barreau de Paris
Toque #C2396
15+ Years In French Corporate Practice
English · French · Russian
Ready When You Are
A 20–30 minute call, in English, to scope the engagement. No obligation, no preliminary fee. You will leave the call with a clear view of what the work will cover and what it will cost.
20+ full codes and 2,400+ articles in English, with the key court rulings linked to every article — free to read.
Read MoreA lawyer-reviewed report explaining how the relevant articles apply to your situation, with case-law analysis and next steps.
Read MoreScope your matter with a Paris-Bar avocate — incorporation, contracts, disputes — handled bilingually, end to end.
Read More